Article Details
Retrieved on: 2018-01-17 20:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>This funding will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company's technology platform and pipeline. <b>Polaris Partners</b>, the founding investor that provided the initial seed funding, co-led the Series A ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here